BTR Capital Management Inc. Acquires 150 Shares of Bio-Rad Laboratories, Inc. (BIO)

BTR Capital Management Inc. lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,120 shares of the medical research company’s stock after purchasing an additional 150 shares during the period. BTR Capital Management Inc.’s holdings in Bio-Rad Laboratories were worth $954,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue increased its stake in Bio-Rad Laboratories by 2.0% during the 4th quarter. State of Alaska Department of Revenue now owns 2,246 shares of the medical research company’s stock valued at $521,000 after purchasing an additional 43 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Bio-Rad Laboratories by 0.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,791 shares of the medical research company’s stock worth $1,345,000 after acquiring an additional 45 shares during the period. LS Investment Advisors LLC increased its stake in shares of Bio-Rad Laboratories by 6.2% in the fourth quarter. LS Investment Advisors LLC now owns 1,411 shares of the medical research company’s stock worth $328,000 after acquiring an additional 82 shares during the period. Virginia Retirement Systems ET AL increased its stake in shares of Bio-Rad Laboratories by 7.1% in the fourth quarter. Virginia Retirement Systems ET AL now owns 1,500 shares of the medical research company’s stock worth $348,000 after acquiring an additional 100 shares during the period. Finally, Brown Advisory Inc. increased its stake in shares of Bio-Rad Laboratories by 15.0% in the fourth quarter. Brown Advisory Inc. now owns 1,067 shares of the medical research company’s stock worth $248,000 after acquiring an additional 139 shares during the period. 64.00% of the stock is owned by hedge funds and other institutional investors.

BIO has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 3rd. Barclays increased their price target on shares of Bio-Rad Laboratories from $315.00 to $340.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Finally, Deutsche Bank increased their price target on shares of Bio-Rad Laboratories from $330.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Bio-Rad Laboratories presently has a consensus rating of “Buy” and an average price target of $359.17.

BIO traded up $2.90 during midday trading on Friday, hitting $301.80. 194,059 shares of the company traded hands, compared to its average volume of 251,933. The company has a quick ratio of 3.19, a current ratio of 4.49 and a debt-to-equity ratio of 0.11. The company has a market cap of $8.79 billion, a price-to-earnings ratio of 51.68, a PEG ratio of 2.75 and a beta of 1.27. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.15.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 28th. The medical research company reported $2.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.52. The business had revenue of $617.54 million for the quarter, compared to the consensus estimate of $610.65 million. Bio-Rad Laboratories had a net margin of 15.76% and a return on equity of 3.92%. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 7.16 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/btr-capital-management-inc-has-954000-holdings-in-bio-rad-laboratories-inc-bio.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: Marijuana Stocks Investing Considerations

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.